Form 4: Timothy A. Springer Reports Acquisition of Cartesian Therapeutics Shares Through Warrant Exercise

Timothy A. Springer, a director and 10% owner of Cartesian Therapeutics, Inc., reports acquiring shares through the exercise of a warrant.

Summary

• On March 26, 2024, Timothy A. Springer acquired 1,970,443 shares of Cartesian Therapeutics, Inc. common stock through the exercise of a warrant at a price of $1.46 per share.
• Following the transaction, Springer directly owns 7,471,625 shares and indirectly owns 33,043,849 shares.
• The indirect ownership includes 86,418 shares held by his wife and shares held by TAS Partners LLC, where Springer is the managing member.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of insider activity. The warrant exercise could be seen as a positive signal, but it's not definitively bullish.

Positives

• The exercise of warrants by a director and significant shareholder could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for signals about management's confidence in the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by a key insider.

Key Dates